|
Synonyms: AK-112 | AK112 | SMT-112 | SMT112
Compound class:
Antibody
Comment: Ivonescimab (AK112/SMT112) is a first-in-class anti-programmed death-1 (PD-1)/VEGF-A bispecific monoclonal antibody. It is designed to simultaneously block both PD-1 and VEGF-mediated immunosuppression in the tumour microenvironment (TME) and inhibit the pro-angiogenic action of VEGF. Interaction of ivonescimab with VEGF-A increases the antibody's avidity for PD-1 and enhances the inhibitory effect on PD-1/PD-L1 signalling [4].
|
| No information available. |
Summary of Clinical Use  |
| Ivonescimab (SMT112) is a clinical candidate for the treatment of advanced solid tumours. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04047290 | A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors | Phase 1 Interventional | Akeso | 1 | |
| NCT05184712 | Phase 3 Clinical Study of AK112 for NSCLC Patients | Phase 3 Interventional | Summit Therapeutics | 2 | |
| NCT04736823 | A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC | Phase 2 Interventional | Akeso | 3 | |
